Table 1.

Demographic and clinical features of plaque− and plaque+ patients. Values are presented as n (%) or mean ± SD.

Features	Plaque−, n = 35	Plaque+, n = 53	p
Male	16 (45.7)	38 (71.7)	0.014^*
Age, yrs	46.57 ± 11.83	53.04 ± 9.33	0.008^*
CV risk factors
BMI	26.26 ± 5.33	25.56 ± 3.72	0.623
Mean systolic blood pressure, mmHg	122.34 ± 18.85	128.53 ± 17.73	0.122
Total cholesterol, mmol/l	5.04 ± 9.39	5.04 ± 0.97	0.996
HDL, mmol/l	1.44 ± 0.44	1.34 ± 0.41	0.298
Triglycerides, mmol/l	1.22 ± 0.56	1.71 ± 1.20	0.014^*
Fasting glucose, mmol/l	5.51 ± 1.90	5.47 ± 1.50	0.921
Hypertension	9 (25.7)	28 (52.8)	0.012^*
Diabetes	4 (11)	9 (17)	0.472
Framingham risk	6.50 ± 5.34	13.53 ± 8.67	< 0.001^*
QRISK2	6.36 ± 6.62	9.60 ± 7.82	0.047^*
HeartScore	0.46 ± 0.82	1.38 ± 1.36	0.001^*
ASCVD	3.40 ± 3.36	6.96 ± 5.29	< 0.001^*
PsA characteristics
PsA disease duration, yrs	8.01 ± 7.75	11.80 ± 1.50	0.076^*
Tender joint count, 0–68	4.49 ± 4.94	5.15 ± 5.98	0.587
Swollen joint count, 0–66	1.26 ± 1.56	1.00 ± 1.53	0.446
Damaged joint count, 0–68	4.57 ± 9.95	6.08 ± 7.80	0.430
Visual analog scale pain, 0–100	43.57 ± 23.34	35.47 ± 24.75	0.128
Patient’s global assessment, 0–100	53.86 ± 23.58	45.66 ± 24.00	0.118
Physician’s global assessment, 0–100	28.85 ± 21.54	35.94 ± 22.62	0.146
PASI, 0–72	5.17 ± 8.33	8.21 ± 9.87	0.136
ESR, mm/1st h	26.94 ± 18.38	29.66 ± 25.09	0.587
CRP, mg/l	5.14 ± 4.85	7.88 ± 8.83	0.066^*
Medications
NSAID	18 (51.4)	30 (56.6)	0.633
DMARD	19 (54.3)	34 (64.2)	0.355
Prednisolone	0 (0.0)	3 (5.8)	0.148

↵* Variables with p value < 0.1 were candidates for multivariate analysis. CV: cardiovascular; BMI: body mass index; HDL: high-density lipoprotein; HeartScore: electronic counterpart of the SCORE risk charts; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; PASI: Psoriasis Area and Severity Index; ASCVD: Atherosclerotic Cardiovascular Disease score; PsA: psoriatic arthritis; DMARD: disease-modifying antirheumatic drug; NSAID: nonsteroidal antirheumatic drug.